Download PDF
Eur J Pediatr Surg 2015; 25(02): 171-176
DOI: 10.1055/s-0033-1357757
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Intravenous Sildenafil in the Management of Pulmonary Hypertension Associated with Congenital Diaphragmatic Hernia

Anja Bialkowski
1   Newborn Intensive Care, Royal Children's Hospital, Melbourne, Victoria, Australia
,
Florian Moenkemeyer
1   Newborn Intensive Care, Royal Children's Hospital, Melbourne, Victoria, Australia
,
Neil Patel
1   Newborn Intensive Care, Royal Children's Hospital, Melbourne, Victoria, Australia
› Author Affiliations
Further Information

Publication History

05 July 2013

29 August 2013

Publication Date:
25 October 2013 (online)

    Permissions and Reprints

Abstract

Background Pulmonary artery hypertension (PAH) is a significant cause of morbidity and mortality in infants with congenital diaphragmatic hernia (CDH). The phosphodiesterase-5 inhibitor sildenafil may be beneficial as a pulmonary vasodilator in CDH. Use of oral preparations of sildenafil may be restricted by feeding delays and intolerance. This study assessed the cardiorespiratory effects of a newly available intravenous (IV) preparation of sildenafil in CDH.

Objectives The objective of the article is to assess the acute effects of IV sildenafil infusion on myocardial function, pulmonary artery pressure (PAP), and oxygenation in infants with CDH.

Methods Retrospective case review of infants with CDH who received continuous IV sildenafil. Physiological and echocardiographic data were reviewed to obtain oxygenation index (OI), PAP, patent ductus arteriosus (PDA) flow, myocardial tissue Doppler velocities, and right ventricular output (RVO) at 48 hours presildenafil, and at 24 to 48 hours and 72 to 96 hours after commencing IV sildenafil.

Results A total of nine infants received IV sildenafil at a dose of 100 to 290 μg/kg/h after CDH repair but before enteral feeding. Pre-IV sildenafil PAP was ≥ systemic blood pressure in all infants, systolic and diastolic right ventricular myocardial velocities were impaired. After 72 to 96 hours of IV sildenafil, OI and Fio 2 were significantly reduced. Ratio of right-to-left to left-to-right PDA flow was > 1 pre-IV sildenafil and < 1 post-IV sildenafil.

Conclusions IV sildenafil infusion was associated with improved oxygenation. Prospective trials of IV sildenafil are required to determine effects on longer term outcome.

Keywords

congenital diaphragmatic hernia - pulmonary hypertension - intravenous sildenafil - phosphodiesterase 5 inhibitor - newborn infant
 

  • References

  • 1 Dillon PW, Cilley RE, Mauger D, Zachary C, Meier A. The relationship of pulmonary artery pressure and survival in congenital diaphragmatic hernia. J Pediatr Surg 2004; 39 (3) 307-312 , discussion 307–312
    CrossrefPubMedGoogle Scholar
  • 2 Wynn J, Krishnan U, Aspelund G , et al. Outcomes of congenital diaphragmatic hernia in the modern era of management. J Pediatr 2013; 163 (1) 114-, e1 DOI: 10.1016/j.jpeds.2012.12.036.
    CrossrefPubMedGoogle Scholar
  • 3 Shah N, Jacob T, Exler R , et al. Inhaled nitric oxide in congenital diaphragmatic hernia. J Pediatr Surg 1994; 29 (8) 1010-1014 , discussion 1014–1015
    CrossrefPubMedGoogle Scholar
  • 4 The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997; 99 (6) 838-845
    CrossrefPubMedGoogle Scholar
  • 5 Everest N, Armstrong R, Hunt R. Neonatal outcomes following the introduction of a time-metered nitric oxide delivery system. J Paediatr Child Health 2012; 48 (S1) A089
    PubMedGoogle Scholar
  • 6 Lakshminrusimha S, Steinhorn RH. Inodilators in nitric oxide resistant persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2013; 14 (1) 107-109
    CrossrefPubMedGoogle Scholar
  • 7 Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011; (8) CD005494
    PubMedGoogle Scholar
  • 8 Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117 (4) 1077-1083
    CrossrefPubMedGoogle Scholar
  • 9 Steinhorn RH, Kinsella JP, Pierce C , et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155 (6) 841-847 , e1
    CrossrefPubMedGoogle Scholar
  • 10 Hunter L, Richens T, Davis C, Walker G, Simpson JH. Sildenafil use in congenital diaphragmatic hernia. Arch Dis Child Fetal Neonatal Ed 2009; 94 (6) F467
    PubMedGoogle Scholar
  • 11 Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004; 5 (2) 184-187
    CrossrefPubMedGoogle Scholar
  • 12 Noori S, Friedlich P, Wong P, Garingo A, Seri I. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 2007; 91 (2) 92-100
    CrossrefPubMedGoogle Scholar
  • 13 Skinner JR, Stuart AG, O'Sullivan J, Heads A, Boys RJ, Hunter S. Right heart pressure determination by Doppler in infants with tricuspid regurgitation. Arch Dis Child 1993; 69 (2) 216-220
    CrossrefPubMedGoogle Scholar
  • 14 Phillipos EZ, Robertson MA, Byrne PJ. Serial assessment of ductus arteriosus hemodynamics in hyaline membrane disease. Pediatrics 1996; 98 (6 Pt 1) 1149-1153
    PubMedGoogle Scholar
  • 15 Tsai-Goodman B, Martin RP, Marlow N, Skinner JR. The repeatability of echocardiographic determination of right ventricular output in the newborn. Cardiol Young 2001; 11 (2) 188-194
    CrossrefPubMedGoogle Scholar
  • 16 Mori K, Nakagawa R, Nii M , et al. Pulsed wave Doppler tissue echocardiography assessment of the long axis function of the right and left ventricles during the early neonatal period. Heart 2004; 90 (2) 175-180
    CrossrefPubMedGoogle Scholar
  • 17 Negrine RJ, Chikermane A, Wright JG, Ewer AK. Assessment of myocardial function in neonates using tissue Doppler imaging. Arch Dis Child Fetal Neonatal Ed 2012; 97 (4) F304-F306
    CrossrefPubMedGoogle Scholar
  • 18 Patel N, Mills JF, Cheung MM. Assessment of right ventricular function using tissue Doppler imaging in infants with pulmonary hypertension. Neonatology 2009; 96 (3) 193-199 , discussion 200–202
    CrossrefPubMedGoogle Scholar
  • 19 De Luca D, Zecca E, Vento G, De Carolis MP, Romagnoli C. Transient effect of epoprostenol and sildenafil combined with iNO for pulmonary hypertension in congenital diaphragmatic hernia. Paediatr Anaesth 2006; 16 (5) 597-598
    CrossrefPubMedGoogle Scholar
  • 20 Filan PM, McDougall PN, Shekerdemian LS. Combination pharmacotherapy for severe neonatal pulmonary hypertension. J Paediatr Child Health 2006; 42 (4) 219-220
    CrossrefPubMedGoogle Scholar
  • 21 Children's Hospital Los Angeles. Ann & Robert H Lurie Children's Hospital of Chicago, University of California, San Francisco. Chronic Sildenafil for Severe Diaphragmatic Hernia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Aug 29]. Available from: http://clinicaltrials.gov/show/NCT00133679 NLM Identifier: NCT00133679
    PubMedGoogle Scholar
  • 22 Stultz JS, Puthoff T, Backes Jr C, Nahata MC. Intermittent intravenous sildenafil for pulmonary hypertension management in neonates and infants. Am J Health Syst Pharm 2013; 70 (5) 407-413
    CrossrefPubMedGoogle Scholar
  • 23 Patel N. Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients. Neonatology 2012; 102 (2) 130-136
    CrossrefPubMedGoogle Scholar